Abstract
IntroductionThe two replicate, randomised, placebo-controlled, 52-week INPULSIS® trials assessed the efficacy and safety of nintedanib 150 mg twice daily (bid) in patients with IPF. The primary endpoint was met in...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have